<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="Cache-Control" content="no-cache, no-store, must-revalidate">
    <meta http-equiv="Pragma" content="no-cache">
    <meta http-equiv="Expires" content="0">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Clinical Outcomes - CRLM LT Clinical Resource</title>
    <link rel="stylesheet" href="../css/style.css?v=1765115033437">
</head>
<body>
    <!-- Navigation -->
    <nav class="navbar">
        <div class="container">
            <div class="logo">CRLM LT Resource</div>
            <button class="hamburger" id="hamburger" aria-label="Toggle menu">
                <span></span>
                <span></span>
                <span></span>
            </button>
            <ul class="nav-menu" id="navMenu">
                <li><a href="../index.html">Home</a></li>
                <li><a href="overview.html">Overview</a></li>
                <li><a href="selection-criteria.html">Selection Criteria</a></li>
                <li><a href="outcomes.html" class="active">Clinical Outcomes</a></li>
                <li><a href="lt-vs-resection.html">LT vs Resection</a></li>
                <li><a href="survival-curves.html">Survival Curves</a></li>
                <li><a href="pdf-resources.html">PDF Resources</a></li>
                <li><a href="patient-flowchart.html">Patient Flowchart</a></li>
                <li><a href="resources.html">Resources</a></li>
                <li><a href="about-research-group.html">About Research Group</a></li>
            </ul>
        </div>
    </nav>

    <!-- Main Content -->
    <main class="content">
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">Home</a> / Clinical Outcomes
            </div>

            <h1>Clinical Outcomes and Survival Data</h1>

            <section class="section">
                <h2>Overall Survival: Key Trials</h2>
                <p>The following table summarizes the major prospective trials evaluating LT for CRLM:</p>

                <table class="data-table">
                    <tr>
                        <th>Trial</th>
                        <th>Year</th>
                        <th>N</th>
                        <th>5-Year OS</th>
                        <th>Key Feature</th>
                    </tr>
                    <tr>
                        <td><strong>SECA-I</strong></td>
                        <td>2013</td>
                        <td>21</td>
                        <td>60%</td>
                        <td>Pilot study, initial evidence</td>
                    </tr>
                    <tr>
                        <td><strong>SECA-II</strong></td>
                        <td>2020</td>
                        <td>25</td>
                        <td>83%</td>
                        <td>Stricter selection criteria</td>
                    </tr>
                    <tr class="highlight-row">
                        <td><strong>TransMet (ITT)</strong></td>
                        <td>2024</td>
                        <td>47</td>
                        <td>56.6%</td>
                        <td>First RCT, LT + Chemo</td>
                    </tr>
                    <tr class="highlight-row">
                        <td><strong>TransMet (Per-Protocol)</strong></td>
                        <td>2024</td>
                        <td>36</td>
                        <td>73.3%</td>
                        <td>First RCT, selected cohort</td>
                    </tr>
                    <tr>
                        <td><strong>Oslo Cohort (61 patients)</strong></td>
                        <td>2023</td>
                        <td>61</td>
                        <td>50.4%</td>
                        <td>Long-term follow-up data</td>
                    </tr>
                </table>
            </section>

            <section class="section">
                <h2>The TransMet Trial: Definitive Evidence</h2>
                <p>The TransMet trial is the first multicenter, randomized controlled trial comparing LT plus chemotherapy to chemotherapy alone:</p>

                <div class="trial-details">
                    <h3>Study Design</h3>
                    <ul>
                        <li><strong>20 European tertiary centers</strong></li>
                        <li><strong>94 patients randomized</strong> (47 LT + Chemo, 47 Chemo alone)</li>
                        <li><strong>Median follow-up:</strong> 59.3 months</li>
                        <li><strong>Inclusion:</strong> Permanently unresectable, liver-only CRLM; BRAF-non-mutated; responsive to chemotherapy</li>
                    </ul>

                    <h3>Primary Endpoint Results</h3>
                    <table class="data-table">
                        <tr>
                            <th>Outcome</th>
                            <th>LT + Chemotherapy</th>
                            <th>Chemotherapy Alone</th>
                            <th>P-value</th>
                        </tr>
                        <tr class="favorable">
                            <td><strong>5-Year OS (ITT)</strong></td>
                            <td>56.6% (95% CI 43.2-74.1)</td>
                            <td>12.6% (95% CI 5.2-30.1)</td>
                            <td>0.0003</td>
                        </tr>
                        <tr class="favorable">
                            <td><strong>5-Year OS (Per-Protocol)</strong></td>
                            <td>73.3% (95% CI 59.6-90.0)</td>
                            <td>9.3% (95% CI 3.2-26.8)</td>
                            <td>&lt;0.001</td>
                        </tr>
                        <tr>
                            <td><strong>Hazard Ratio</strong></td>
                            <td colspan="2">0.37 (95% CI 0.21-0.65)</td>
                            <td>â€”</td>
                        </tr>
                    </table>

                    <div class="interpretation-box">
                        <strong>Interpretation:</strong> LT plus chemotherapy reduces the risk of death by 63% compared to chemotherapy alone. This represents a 4.5-fold improvement in survival.
                    </div>
                </div>
            </section>

            <section class="section">
                <h2>Disease-Free Survival and Recurrence Patterns</h2>
                <p>One of the most important findings in LT for CRLM is the discrepancy between disease-free survival (DFS) and overall survival (OS):</p>

                <div class="highlight-box">
                    <h3>The Recurrence Paradox</h3>
                    <ul>
                        <li><strong>Median DFS:</strong> 11.8 months (Oslo cohort)</li>
                        <li><strong>5-Year DFS:</strong> 18.3% (Oslo cohort)</li>
                        <li><strong>Recurrence Rate:</strong> 78.3% of patients</li>
                        <li><strong>Median Time to Recurrence:</strong> 9.0 months</li>
                        <li><strong>94% of recurrences:</strong> Within 2 years of LT</li>
                    </ul>
                </div>

                <h3>Survival After Recurrence</h3>
                <p>Despite the high recurrence rate, survival after relapse is remarkably good:</p>
                <ul>
                    <li><strong>Median OS from time of relapse:</strong> 37.1 months</li>
                    <li><strong>5-Year survival after relapse:</strong> 34.8%</li>
                    <li><strong>14 of 47 patients (29.8%):</strong> Alive &gt;5 years after diagnosis of recurrence</li>
                    <li><strong>One patient:</strong> Alive 156 months (13 years) after relapse</li>
                </ul>

                <div class="clinical-note">
                    <strong>Clinical Significance:</strong> The indolent pattern of recurrence suggests that total hepatectomy effectively removes the primary tumor burden, while residual disease exhibits slower growth kinetics. This is distinct from the aggressive nature of CRLM in non-transplant patients.
                </div>
            </section>

            <section class="section">
                <h2>Comparative Analysis: LT vs. Alternative Approaches</h2>

                <h3>LT vs. Portal Vein Embolization + Liver Resection</h3>
                <p>For patients with high tumor load (HTL), LT offers superior outcomes compared to PVE followed by liver resection:</p>

                <table class="data-table">
                    <tr>
                        <th>Treatment</th>
                        <th>HTL Patients</th>
                        <th>5-Year OS</th>
                    </tr>
                    <tr class="favorable">
                        <td><strong>LT (all HTL)</strong></td>
                        <td>29 patients</td>
                        <td>33.4%</td>
                    </tr>
                    <tr>
                        <td><strong>PVE + LR (all HTL)</strong></td>
                        <td>15 patients</td>
                        <td>19.2%</td>
                    </tr>
                    <tr class="highlight-row">
                        <td><strong>LT (HTL + Left-sided)</strong></td>
                        <td>Subset</td>
                        <td>45.3%</td>
                    </tr>
                    <tr class="highlight-row">
                        <td><strong>PVE + LR (HTL + Left-sided)</strong></td>
                        <td>Subset</td>
                        <td>12.5%</td>
                    </tr>
                </table>

                <p><strong>Key Finding:</strong> For patients with extensive disease and left-sided primary tumors, LT provides a 3.6-fold improvement in 5-year OS compared to PVE and resection.</p>
            </section>

            <section class="section">
                <h2>Outcomes by Risk Stratification</h2>

                <h3>Oslo Score Impact</h3>
                <table class="data-table">
                    <tr>
                        <th>Oslo Score</th>
                        <th>Median OS</th>
                        <th>5-Year OS</th>
                        <th>10-Year OS</th>
                    </tr>
                    <tr class="favorable">
                        <td><strong>0-1</strong></td>
                        <td>92.0 months</td>
                        <td>63.4%</td>
                        <td>45.7% - 88.9%</td>
                    </tr>
                    <tr class="intermediate">
                        <td><strong>2</strong></td>
                        <td>~70 months</td>
                        <td>~60%</td>
                        <td>~45%</td>
                    </tr>
                    <tr class="unfavorable">
                        <td><strong>3-4</strong></td>
                        <td>24.8 months</td>
                        <td>8.3%</td>
                        <td>0%</td>
                    </tr>
                </table>

                <p><strong>Clinical Implication:</strong> Patients with Oslo Score 0-1 achieve 10-year OS rates comparable to traditional LT indications, justifying the use of donor organs.</p>
            </section>

            <section class="section">
                <h2>Living Donor Liver Transplantation (LDLT)</h2>
                <p>LDLT offers an alternative to deceased donor LT and may provide superior outcomes:</p>

                <div class="highlight-box">
                    <h3>North American LDLT Experience</h3>
                    <ul>
                        <li><strong>First 10 LDLT cases:</strong> 1.5-year OS of 100%, DFS of 62%</li>
                        <li><strong>US cohort (56.5% LDLT):</strong> 3-year OS 71.4% (LDLT) vs. 51.4% (DDLT)</li>
                        <li><strong>Advantages:</strong> Shorter cold ischemia time, better graft quality, shorter waitlist time</li>
                        <li><strong>Donor safety:</strong> Acceptable perioperative morbidity in living donors</li>
                    </ul>
                </div>

                <p><strong>Implication:</strong> LDLT circumvents deceased donor scarcity and may be the preferred approach in centers with experience in living donor transplantation.</p>
            </section>

            <section class="section">
                <h2>Serious Adverse Events</h2>
                <p>The safety profile of LT for CRLM is important to consider:</p>

                <table class="data-table">
                    <tr>
                        <th>Complication</th>
                        <th>Incidence</th>
                        <th>Notes</th>
                    </tr>
                    <tr>
                        <td>Serious Adverse Events (LT)</td>
                        <td>80% (32/40 patients)</td>
                        <td>Comparable to other LT indications</td>
                    </tr>
                    <tr>
                        <td>Serious Adverse Events (Chemo)</td>
                        <td>83% (45/54 patients)</td>
                        <td>Chemotherapy-related toxicity</td>
                    </tr>
                    <tr>
                        <td>Retransplantation</td>
                        <td>3 cases (TransMet)</td>
                        <td>One perioperative death</td>
                    </tr>
                </table>

                <p><strong>Interpretation:</strong> The safety profile of LT is comparable to chemotherapy alone, with serious adverse events occurring in both groups at similar rates.</p>
            </section>

            <section class="section">
                <h2>Summary of Key Outcomes</h2>
                <div class="summary-box">
                    <ul>
                        <li><strong>LT + Chemotherapy vs. Chemotherapy Alone:</strong> 56.6% vs. 12.6% 5-year OS (HR 0.37, p=0.0003)</li>
                        <li><strong>Best Outcomes:</strong> Oslo Score 0-1 patients achieve 10-year OS of 88.9%</li>
                        <li><strong>Recurrence is Common:</strong> 78.3% of patients experience recurrence, but median OS after relapse is 37.1 months</li>
                        <li><strong>LDLT Advantage:</strong> 3-year OS 71.4% vs. 51.4% for DDLT</li>
                        <li><strong>HTL + Left-sided Tumors:</strong> LT 5-year OS 45.3% vs. PVE+LR 12.5%</li>
                    </ul>
                </div>
            </section>

            <section class="section call-to-action">
                <h2>Next Steps</h2>
                <p>For additional resources, guidelines, and ongoing clinical trials, visit the <a href="resources.html">Resources</a> page.</p>
            </section>
        </div>
    </main>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <p>&copy; 2025 CRLM LT Clinical Resource. Evidence-based information for transplant teams.</p>
            <p class="author"><strong>Created by:</strong> Tor Magnus Smedman, MD PhD | Transplant Oncology Research Group, Oslo University Hospital</p>
            <p class="disclaimer">This resource is for educational purposes. Clinical decisions should be made in consultation with a multidisciplinary team.</p>
        </div>
    </footer>

    <script src="../js/main.js?v=1765115033437"></script>
    <script>
        // Hamburger menu toggle
        const hamburger = document.getElementById("hamburger");
        const navMenu = document.getElementById("navMenu");
        
        if (hamburger && navMenu) {
            hamburger.addEventListener("click", function() {
                navMenu.classList.toggle("active");
                hamburger.classList.toggle("active");
            });
            
            // Close menu when a link is clicked
            const navLinks = navMenu.querySelectorAll("a");
            navLinks.forEach(link => {
                link.addEventListener("click", function() {
                    navMenu.classList.remove("active");
                    hamburger.classList.remove("active");
                });
            });
        }
    </script>
</body>
</html>
